The Latest Breaking News from Danaher

Healthcare giant Danaher is set to unveil its fourth-quarter earnings later this month and analysts expect a modest single-digit growth in earnings.

Danaher has underperformed the Medical Devices industry, though Wall Street analysts remain strongly optimistic about its future prospects.

Although Danaher has underperformed relative to the broader market over the past year, Wall Street analysts maintain a bullish outlook about the stock’s prospects.

With Danaher gearing up to release its third-quarter earnings later this month, analysts expect double-digit earnings decline.

Danaher recently underperformed the healthcare sector, but Wall Street analysts are moderately bullish about the stock’s prospects.

Danaher has lagged behind the broader market over the past year, yet analysts remain moderately bullish on the stock’s prospects.

Danaher stock flirted with a breakout Tuesday on the back of its unexpectedly strong sales from its molecular testing services.

Danaher shows rising price performance, earning an upgrade to its IBD Relative Strength Rating

The S&P 500 Index ($SPX ) (SPY ) Tuesday closed up +1.20%, the Dow Jones Industrials Index ($DOWI ) (DIA ) closed up +0.69%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed up +1.51%. US stock indexes closed moderately higher on Tuesday, with the Dow Jones Industrials climbing...

PulteGroup received an added data boost, Danaher's markets are looking up, and JetBlue collapses, despite a not-as-bad-as-feared loss.

In the specialized field of spinoff companies, Veralto emerges as a prime investment opportunity, stemming from its recent spinoff from Danaher Corporation.